1st generation drug-eluting stents (DES) have been shown to reduce restenosis and target vessel revascularizations (TVR) compared with bare-metal stents (BMS) in patients with STEMI
1st generation DES have also been associated with increased rates of very late stent thrombosis (ST), raising concerns over the safety of these devices in patients with STEMI, who compared to patients with stable coronary artery disease, have greater rates of ST due to heightened platelet activation and the presence of thrombus
The most important finding in this study is the significantly reduced risk of 1-year cardiac death, MI, and ST with CoCr-EES (cobalt-chromium everolimus eluting stent) compared to BMS
The observed reduction in MI, ST, and composite cardiac death rates with CoCr-EES compared to BMS is consistent with experimental data suggesting that stents covered by fluorinated polymers are less thrombogenic than even BMS
References
Palmerini T, et al. Clinical Outcomes With Drug-Eluting and Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Elevation. JACC. 2-13, Vol. 62:2 pgs.196-504
